



Broadview Ventures Promotes David Prim to *Principal of Broadview Ventures*

Boston, Massachusetts, September 3, 2024

Broadview Ventures, a mission-driven investment organization dedicated to accelerating the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke, today announces the promotion of David Prim, PhD, to Principal.

Since joining Broadview Ventures as a Senior Associate in 2021, David has sourced, evaluated, and closed several key medical device investments, and has partnered closely with existing portfolio companies to help guide their operational and corporate development. David currently serves on the boards of CorFlow Therapeutics, Puzzle Medical Devices, and Vascular Graft Solutions. In the Principal role, David will continue to expand his responsibility in sourcing new opportunities; leading scientific, clinical, and corporate due diligence efforts; structuring transactions; and managing portfolio company investments.

Broadview is committed to the career progression and recognition of its investment team members. Over the last three and a half years, David has demonstrated the ability to identify high-potential founders, execute investment due diligence, lead and syndicate investments, and promote the success of management teams. We are pleased to formally recognize David's talent and accomplishments with his promotion to Principal.

We look forward to continued partnership with David in this new role.

Christopher H. Colecchi
Managing Director

To learn more about Broadview's portfolio and activities, please visit our [website](#).

Broadview Ventures | 265 Franklin Street | Boston, MA 02110 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!